Cantor Sees New Dendreon CEO as Good, Molycorp Lacks Strategic Benefit

Dendreon Corp. (NASDAQ:DNDN): Cantor believes John Johnson’s background in marketing and cost structure could lead to a restructuring within Dendreon in 2012. The firm views the CEO transition to Johnson as a good move for Dendreon but keeps a Hold rating on the stock.

Thermo Fisher Scientific, Inc. (NYSE:TMO): Cantor increased its target on Thermo Fisher after the company reported stronger than expects Q4 results. The firm thinks that the company is continuing to execute well, and maintains a Buy rating.

Express Scripts Inc. (NASDAQ:ESRX): Deutsche Bank said Express Scripts’ (NASDAQ:ESRX) Plan D enrollment was up mid-single digits sequentially and supports its view it will retain greater than 95% of the scripts Walgreen (NYSE:WAG) used to service. The firm views this as an incremental negative datapoint for Walgreen indicating retention of Express Script’s scripts will be difficult.

Molycorp, Inc (NYSE:MCP): JP Morgan does not see any strategic benefit or synergies between Molycorp and Chile’s Molymet.

Auxilium Pharmaceuticals Inc.(NASDAQ:AUXL): Auxilium removed from short-term buy list at Deutsche Bank

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com